Because MANAGEMENT has been raping the SH for years now and until DSCO get NEW management or gets bought out, its going nowhere. WALL STREET HATES DSCO !!!!!!!!!!!!! can you tell ?
Will be a HUGE year for ARRY look for heavy accumulation going into ASH 2013
Four abstracts on ARRY-520 have been submitted for presentation at the 2013 American Society of Hematology (ASH) Annual Meeting in December 2013. These include data from the following studies: ARRY-520 plus dexamethasone, ARRY-520 plus Kyprolis, ARRY-520 plus Velcade and preclinical data regarding ARRY-520 plus Pomalyst. ASH is the world's largest professional society concerned with the causes and treatments of blood disorders.
If you are long hold tight they did the same thing with JAZZ and ONXX take a look at them now, VERY BULLISH IMO big boys wanting more shares. I know it hard to swallow but true.
Loxo Oncology, Inc., a biopharmaceutical company focused on targeted cancer therapies for genetically-defined populations, announced today that its lead clinical program is a potent and selective inhibitor of the Trk family of receptor tyrosine kinases. Loxo Oncology acquired rights to this program from Array Biopharma (NASDAQ:ARRY), which had pursued a multi-year discovery effort to design purpose-built compounds that spare structurally similar kinase targets, such as ALK, JAK and VEGF.
HOLD on to your DNDN shares, place a sell order above 25.00 so they cannot borrow your shares to short it, then just sit back and wait :)
Also ARRY will post some GOOD news tomorrow :) birdie says so.......
birdie was right I guess :)
next up is ARRY from what I am hearing last couple days..............but this will take a little longer, take a look at their pipeline :)